ArticleSage open pathology
Diagnostic Utility of the Sydney System in Lymph Node Cytopathology: A Retrospective Analysis.
Article in Sage open pathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fine-needle aspiration biopsy (FNAB) is a widely used technique for the evaluation of lymphadenopathy. The recently proposed Sydney System offers a framework for the categorization, evaluation, and reporting of lymph node cytopathology. This study aimed to assess the diagnostic accuracy and risk of malignancy (ROM) for each diagnostic category of the Sydney system. Methods: A two-year retrospective single-center study analyzed 392 lymph node FNAB cases, and categorized according to the proposed Sydney system. The findings were tabulated and analyzed using Jamovi (Version 2.5) and SPSS version 26.0. Results: Of the 392 lymph node FNAB cases, 72 (18%) had histopathological follow-up. The mean age of the patients was 44 years, with a range of 1-90 years. A slight male predominance was seen, with male to female ratio of 1.17: 1. The cervical group was the most commonly aspirated node (n=241, 61%). Using the Sydney System, 69 (17.6%) were classified in the non-diagnostic/inadequate category, 211 (54%) were reported as benign (L2), 5 (1.2%) as atypical cells of undetermined significance (L3), 2 (0.5%) as suspicious for malignancy (L4), and 105 (26.7%) as malignant (L5). The sensitivity was 96.8%(95% CI: 82.8% to 99.4%), specificity was 96.6%(95% CI: 83.8% to 99.4%), positive predictive value was 96.8%(95% CI: 83.8% to 99.4%), negative predictive value was 96.6%(95% CI: 82.8% to 99.4%), and diagnostic accuracy was 96.7% (95% CI: 88.7% to 99.1%) for the verified subset(n=60). The risk of malignancy was 46.7% to 91.1% for the inadequate category, 0.6% to 17.2% for the benign category, and 88.6% to 100% for the malignant category. ROM was not calculated for L3 and L4 due to the absence of malignant cases and a very small sample size. Conclusion: The Sydney System provides precise, standardized lymph node FNAB reporting, enhancing diagnostic accuracy, risk assessment, and informed clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.